These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2393882)

  • 21. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibody formation after filtered blood cell replacement in hematologic-oncologic patients].
    Barz D; Staack D; Lehmann R; Stange K; Schnurstein K
    Beitr Infusionsther Transfusionsmed; 1996; 33():30-4. PubMed ID: 8974705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.
    Snyder EL
    Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HLA compatibility and survival of 51 chromium-labeled allogeneic thrombocytes].
    Májský A; Fortýnová J; Vopatová M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):831-7. PubMed ID: 6176508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Failure of therapy with thrombocyte concentrates as a sequela of anti-Kob (3b) antibodies in a patient].
    Májský A; Korínková P; Cermák J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):944-9. PubMed ID: 2419225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of platelet aggregation induced by HLA-related antibodies.
    Brandt JT; Julius CJ; Osborne JM; Anderson CL
    Thromb Haemost; 1996 Nov; 76(5):774-9. PubMed ID: 8950789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thrombocyte substitution. I. Indications and clinical use of thrombocyte transfusion].
    Anders O; Preussner S; Konrad H
    Z Gesamte Inn Med; 1986 Nov; 41(21):592-5. PubMed ID: 3825211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Transfusion-refractory thrombocytopenia during chemotherapy: pathogenesis, frequency and treatment].
    Helleberg C; Taaning EB; Johnsen HE
    Ugeskr Laeger; 1995 Sep; 157(37):5082-6. PubMed ID: 7502374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
    Lo SC; Chang JS; Lin SW; Lin DT
    Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Supportive haemotherapy in bone marrow transplantation.
    Mayr WR
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):455-8. PubMed ID: 2480289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and natural history of alloimmunization following HLA-matched leukocyte transfusion in Hunter's syndrome.
    Kakaiya RK; Greenstein R; Pisciotto PT; Slocum SK; Rosen D; Cable RG; Morse EE
    Ann Clin Lab Sci; 1984; 14(4):276-84. PubMed ID: 6431893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of HLA antibodies in thrombocyte substitution with cell separator products].
    Koepsell E; Zumpe P; Saavedra C; Seidl S
    Beitr Infusionsther; 1992; 30():416-9. PubMed ID: 1284749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-leukocyte and anti-platelet immunization and transfusions during aplastic anemias].
    Dausset J; Benbunan M
    Nouv Rev Fr Hematol (1978); 1976 Jun; 16(1):132-43. PubMed ID: 781619
    [No Abstract]   [Full Text] [Related]  

  • 38. Unrecognized causes of platelet transfusion failure in the presence of anti-HL-A antibodies.
    Hattersley PG
    West J Med; 1977 Apr; 126(4):263-6. PubMed ID: 855318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions.
    Fisher M; Chapman JR; Ting A; Morris PJ
    Vox Sang; 1985; 49(5):331-5. PubMed ID: 3909636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.
    Saris A; Kerkhoffs JL; Norris PJ; van Ham SM; Ten Brinke A; Brand A; van der Meer PF; Zwaginga JJ
    Transfusion; 2019 Feb; 59(2):470-481. PubMed ID: 30499599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.